Drugs / FHND5071
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05818917 | Jul 2022 → Dec 2023 | cancer | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-05-26 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Regulatory 正大丰海新一代RET抑制剂FHND5071 IND申请获美国FDA批准 ctfh.com.cn ↗
美国食品药品监督管理局（FDA）于2022年05月25日批准我司新一代RET抑制剂FHND5071在美国开展药物临床试验。 |
| 2022-05-06 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Regulatory 我司自主研发的创新药IND申请首次获得美国FDA受理 ctfh.com.cn ↗
我司于 2022 年 05 月收到美国食品药品监督管理局（ FDA ）的书面回复，用于治疗晚期实体瘤的 FHND5071 临床试验申请（ IND ）获得正式受理。 |
| 2022-03-26 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Regulatory 正大丰海制药抗肿瘤1类新药FHND5071临床试验申请成功获批 ctfh.com.cn ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-05-26 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | 正大丰海新一代RET抑制剂FHND5071 IND申请获美国FDA批准 ctfh.com.cn ↗ |
| 2022-05-06 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | 我司自主研发的创新药IND申请首次获得美国FDA受理 ctfh.com.cn ↗ |
| 2022-03-26 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | 正大丰海制药抗肿瘤1类新药FHND5071临床试验申请成功获批 ctfh.com.cn ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FHND5071 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05818917 ↗ |
| Route | Oral | “FHND5071 will be administered orally” NCT05818917 ↗ |